Business Description
Ventyx Biosciences Inc
NAICS : 541713
SIC : 2833
ISIN : US92332V1070
Description
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 24.9 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -39 | |||||
| 3-Year EPS without NRI Growth Rate | -111.1 | |||||
| 3-Year FCF Growth Rate | -113.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 13.81 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.72 | |||||
| 9-Day RSI | 47.89 | |||||
| 14-Day RSI | 49.45 | |||||
| 6-1 Month Momentum % | -26.29 | |||||
| 12-1 Month Momentum % | -16.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 23.52 | |||||
| Quick Ratio | 23.52 | |||||
| Cash Ratio | 22.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -41 | |||||
| Shareholder Yield % | -64.39 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -54.7 | |||||
| ROA % | -49.46 | |||||
| ROIC % | -739.06 | |||||
| ROC (Joel Greenblatt) % | -1283.19 | |||||
| ROCE % | -57.44 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.59 | |||||
| Price-to-Tangible-Book | 0.59 | |||||
| EV-to-EBIT | 0.63 | |||||
| EV-to-Forward-EBIT | -0.45 | |||||
| EV-to-EBITDA | 0.63 | |||||
| EV-to-Forward-EBITDA | -2.58 | |||||
| EV-to-FCF | 0.66 | |||||
| Price-to-Net-Current-Asset-Value | 0.6 | |||||
| Price-to-Net-Cash | 0.63 | |||||
| Earnings Yield (Greenblatt) % | 158.73 | |||||
| FCF Yield % | -96.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VTYX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ventyx Biosciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.36 | ||
| Beta | 0.46 | ||
| Volatility % | 253.54 | ||
| 14-Day RSI | 49.45 | ||
| 14-Day ATR ($) | 0.225253 | ||
| 20-Day SMA ($) | 2.5025 | ||
| 12-1 Month Momentum % | -16.29 | ||
| 52-Week Range ($) | 1.67 - 11.48 | ||
| Shares Outstanding (Mil) | 70.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ventyx Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ventyx Biosciences Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ventyx Biosciences Inc Frequently Asked Questions
What is Ventyx Biosciences Inc(VTYX)'s stock price today?
The current price of VTYX is $2.27. The 52 week high of VTYX is $11.48 and 52 week low is $1.67.
When is next earnings date of Ventyx Biosciences Inc(VTYX)?
The next earnings date of Ventyx Biosciences Inc(VTYX) is 2025-02-27 Est..
Does Ventyx Biosciences Inc(VTYX) pay dividends? If so, how much?
Ventyx Biosciences Inc(VTYX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers